ライフサイエンスコーパス: angiotensin II

1 ((13)C(6)-ochratoxin A), and an octapeptide (angiotensin II).

2 ectomy) and a hypertension model (induced by angiotensin II).

3 to myofibroblasts in the presence of Ang II (angiotensin II).

4 of the most potent vasoconstrictors, peptide angiotensin II.

5 s suppressed the vasoconstrictor response to angiotensin II.

6 blast transformation induced by TGFbeta1 and angiotensin II.

7 hancement, 100 picomole) in the detection of angiotensin II.

8 ility to remodel cardiac tissue and generate angiotensin II.

9 thout influencing the hypertensive effect of angiotensin II.

10 s is a systematic review of the safety of IV angiotensin II.

11 ce with a combination of a high-fat diet and angiotensin II.

12 f post-pneumonectomy vasoplegia managed with angiotensin II.

13 between ACE and ACE2 result in an unopposed angiotensin II.

14 containing saline or a slow-pressor dose of angiotensin II (0.25 mg.kg(-1).d(-1)).

15 ipoprotein E knockout mice were infused with angiotensin II (0.72 mg.kg(-1).d(-1) subcutaneous) for 2

16 nsion, wild-type NMRI mice were infused with angiotensin II (1.44 mg.kg(-1).d(-1) subcutaneous) for 1

17 ipumps with a continuous infusion of Ang II (angiotensin II; 1000 ng/[kg.min]) to induce AAAs were im

18 Activation of AT1 R with angiotensin II (30 nm) also increased TRPM4 currents in

19 e to 2 weeks of continuous administration of angiotensin II, a profibrotic stimulus that drives patho

20 IK(Na) is negatively regulated by angiotensin II acting through Galphaq protein-coupled re

21 actors implicated in muscle atrophy, such as angiotensin-II, activin and Acvr2b, in SIRT6 depleted ce

22 ilar levels of hypertension after 2 weeks of angiotensin II administration.

23 of intrakidney paracrine hormones including angiotensin II, aldosterone, and endothelin-1 (ET-1) tha

24 these adaptive responses; reduces levels of angiotensin II, aldosterone, and ET-1; reduces ammoniage

25 activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprilysin) impair insu

26 activity repressed by albumin, high glucose, angiotensin II, aldosterone, cisplatin and lipopolysacch

27 Angiotensin II also reduced vasoconstriction stimulated

28 wed an elevated contractile response to 5 nM angiotensin II and a loss of acetylcholine (ACh)-mediate

29 levels of anti-natriuretic hormones, such as angiotensin II and aldosterone; and adipokines, particul

30 injury (post-AKI) rats were stimulated with angiotensin II and elevated Na+ (10-7 M/170 mM) in vitro

31 damental unit of zG layer activity evoked by angiotensin II and highlight a novel role for the rosett

32 ctor (HIF)-1alpha and -2alpha in response to angiotensin II and hypoxia, respectively, which drive VE

33 orescence in response to exogenously applied angiotensin II and III, but not other common neurotransm

34 ll response to isoproterenol, phenylephrine, angiotensin II and stretch.

35 Furthermore, the cellular responses to angiotensin II and the relative abundance of fibrogenic

36 rch is warranted to determine the utility of angiotensin II and to better understand it effects on th

37 synthesis of its main effector peptides Ang (angiotensin) II and Ang (1-7).

38 ress, and hypertrophy and attenuates Ang II (angiotensin II) and deoxycorticosterone acetate-salt ind

39 received a study intervention (163 received angiotensin II, and 158 received placebo) and were inclu

40 ore age 60, blunted hypertensive response to angiotensin II, and a leftward shift in pressure natriur

41 o-HDL cholesterol ratio, C-reactive protein, angiotensin II, and albuminuria reduction and with incre

42 timulated cGMP generation, suppressed plasma angiotensin II, and reduced cardiac filling pressures wi

43 increasing size, including the octapeptide, angiotensin II, and the nonapeptide, oxytocin.

44 istration of vasoconstrictive agents such as angiotensin II (Ang II) and phenylephrine results in an

45 Aging WT brains had high levels of angiotensin II (Ang II) and ROS production; activation o

46 K mutation in mice subjected to high salt or angiotensin II (Ang II) as models of hypertension and in

47 ced using beta-aminopropionitrile (BAPN) and angiotensin II (Ang II) infusion (2 weeks).

48 oconstrictor and a proinflammatory mediator, angiotensin II (Ang II) is considered a potential link b

49 Losartan, an angiotensin II (Ang II) receptor blocker acting on the A

50 Angiotensin II (Ang II) stimulation induced trafficking

51 Activation of the AT1 receptor by angiotensin II (Ang II) triggered transactivation of the

52 um influx, and we have previously shown that angiotensin II (Ang II) via canonical transient receptor

53 We show that angiotensin II (Ang II), a vasoconstrictor, stimulates d

54 nsin-converting enzymes (ACEs) ACE and ACE2, angiotensin II (Ang II), Ang-(1-7), and receptors AT1 an

55 rmone of the renin-angiotensin system (RAS), angiotensin II (Ang II), is involved in several human di

56 rbate vascular senescence and progression of angiotensin II (Ang II)-induced AAA by facilitating reac

57 Loss of APLN potentiated angiotensin II (Ang II)-induced AAA formation, aortic ru

58 cells in the aorta due to the attenuation of Angiotensin II (Ang II)-induced HSC expansion.

59 ing pathways involved in the effect of LC on angiotensin II (Ang II)-induced NADPH oxidase activation

60 eceptor") that results in tissue injury from angiotensin II (Ang II)-mediated signaling.

61 ion of collagen alpha1(I) gene expression in angiotensin II (Ang II)-stimulated cardiac fibroblasts.

62 The two vasoactive hormones, angiotensin II (ANG II; vasoconstrictive) and atrial nat

63 cally transforms Ang-I to a secondary ligand angiotensin II (Ang-II) that has the potential to bind i

64 This study tests a direct role of IgE in angiotensin-II (Ang-II) perfusion- and peri-aortic CaCl(

65 converting enzyme 2 (ACE2) promotes the ACE/angiotensin-II (Ang-II)/angiotensin type 1 receptor (AT1

66 as profiles: the balanced endogenous agonist angiotensin II (AngII) and two strongly beta-arrestin-bi

67 NaCl concentrations and the peptide hormone angiotensin II (AngII) are two major neurohumoral signal

68 Using angiotensin II (AngII) as the prototypical inducer of IF

69 Although exogenous angiotensin II (AngII) can increase NMDAR activity in th

70 ding partners and that activation of AT1R by angiotensin II (ANGII) elicits beta-arrestin-dependent i

71 E knockout (ApoE-KO) mice were infused with angiotensin II (AngII) for 28 days to induce AAA formati

72 We present evidence that following angiotensin II (AngII) infusion the TNFalpha type 1 rece

73 sly three times a week starting at day 28 of angiotensin II (AngII) infusion.

74 Although angiotensin II (AngII) is known to cause renal injury an

75 Inhibition of angiotensin II (AngII) signaling, a therapeutic mainstay

76 switching to a similar extent as TGFbeta1 or angiotensin II (ANGII) stimulation.

77 merulosa (ZG) under the control of the renin-angiotensin II (AngII) system.

78 esponse to TGF-beta, increased expression of angiotensin II (AngII) type 1 receptor (Agtr1a), enhance

79 The angiotensin II (AngII) type 1 receptor (AT1R) is a criti

80 The angiotensin II (AngII) type 1 receptor (AT1R) is a membe

81 The angiotensin II (AngII) type 1 receptor (AT1R), a member

82 udies have shown that serelaxin requires the angiotensin II (AngII) type 2 receptor (AT(2)R) to ameli

83 The OVLT also expresses the angiotensin II (AngII) type1 receptor, and AngII increas

84 e RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (

85 ocytes and tubular epithelia and metabolizes angiotensin II (AngII), a peptide known to promote glome

86 Our studies have highlighted angiotensin II (AngII), a vasoactive hormone, as a poten

87 An Angiotensin II (AngII)-aldosterone (Ald) infusion mouse

88 e upregulated during hypertension induced by angiotensin II (AngII).

89 ntity during homeostasis, and in response to angiotensin-II (AngII)-induced arterial inflammation.

90 The angiotensin converting enzyme-1-angiotensin II-angiotensin AT(1) receptor pathway contri

91 The angiotensin-II antagonist losartan is a promising candid

92 associated with higher risk for AMI; whereas angiotensin-II-antagonists, calcium-channel blockers, an

93 Angiotensin II (applied for 2 h) reduced surface and tot

94 and hemodynamic responses to an infusion of angiotensin II (assessment of intrarenal renin-angiotens

95 nction in rats, and the impact of intrarenal angiotensin II AT(1) receptor blockade using candesartan

96 Furthermore, blockade of the angiotensin II AT(1) receptor restored cortical partial

97 These results suggest that blockade of angiotensin II AT(1) receptors has a major impact upon o

98 ind that increased complex formation between angiotensin II AT1 and bradykinin B2, two G protein-coup

99 s reversed by an ACE inhibitor but not by an angiotensin II AT1 receptor antagonist.

100 Sodium deficiency increases angiotensin II (ATII) and aldosterone, which synergistic

101 tensin-converting enzyme or the receptor for angiotensin II attenuated VEGF-mediated relaxation of th

102 ensin-converting enzyme) inhibitors and ANG (angiotensin) II blockers, neprilysin inhibitors, and ald

103 In euvolemic rats, the dipsogenic hormone angiotensin II, but not the orexigenic hormone ghrelin,

104 where these tumor cells autocrinely produce angiotensin II by a chymase-dependent rather than an ang

105 critical role of hypoxia in producing local angiotensin II by a lactate-chymase-dependent mechanism

106 by subcutaneous infusion of either saline or Angiotensin II by osmotic minipumps.

107 Angiotensin II caused a significant increase in mean art

108 t Shock) trial for renin, angiotensin I, and angiotensin II concentrations before the start of admini

109 RGS2 LOF mutants failed to suppress the angiotensin II constriction response compared with RGS2

110 Angiotensin II, converted by angiotensin-converting enzy

111 echanistically, we found that Plk1 regulated angiotensin II-dependent activation of RhoA and actomyos

112 e protected against vascular remodelling and angiotensin II-dependent inflammation.

113 explore the repurposing of drugs that target angiotensin II-dependent NFkappaB signaling pathways to

114 MC-deficient mice administered angiotensin II did not develop fibrosis; MC-deficient mi

115 included number of subjects, comorbidities, angiotensin II dose and duration, pressor effects, other

116 Angiotensin II effectively increased blood pressure in p

117 Here we demonstrate that within the rosette, angiotensin II evokes periodic Ca(v)3-dependent calcium

118 In WT mice, administration of angiotensin II for 2 weeks downregulated collectrin expr

119 sex chromosome complement were infused with angiotensin II for 28 days to induce AAAs.

120 mples from patients enrolled in the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) t

121 We investigated the effectiveness of angiotensin II for the treatment of patients with this c

122 immune homeostasis independently of canonic angiotensin II generation.

123 nd point was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than i

124 ere reported in 60.7% of the patients in the angiotensin II group and in 67.1% in the placebo group.

125 occurred in 75 of 163 patients (46%) in the angiotensin II group and in 85 of 158 patients (54%) in

126 more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs

127 s systematic review supports the notion that angiotensin II has an acceptable safety profile for use

128 Angiotensin II has been implicated in maladaptive right

129 (transforming growth factor beta) and AngII (angiotensin II), have been well characterized, less unde

130 ssed by acetylcholine, albumin, aldosterone, angiotensin II, high glucose, cisplatin and lipopolysacc

131 otensin peptides revealed elevated levels of angiotensin II, III, IV, and 1-5 in DPP3(-/-) mice, wher

132 was fatal in 55 of 115 patients treated with angiotensin II in case studies, cohort studies, and one

133 Our data reveal a critical role for angiotensin II in regulating burst occurrence, and a mul

134 hanism and highlight the importance of local angiotensin II in regulating radioresistance of hypoxic

135 ension, and an impaired arterial response to angiotensin II in vivo.

136 Chronic infusion of angiotensin-II in atheroprone (ApoE(-/-)) mice provides

137 The levels of ET-1(endothelin-1) and Ang II (Angiotensin II) in the plasma were measured by an enzyme

138 hermore, telemetry studies showed that while angiotensin II increased blood pressure acutely in all a

139 Rationale: Exogenous angiotensin II increases mean arterial pressure in patie

140 c-expressing myeloid cells mitigates Ang II (angiotensin II)-induced hypertension by limiting renal T

141 ersus male (XY) sex chromosome complement on angiotensin II-induced AAA formation and rupture in phen

142 female mice exhibit far lower incidences of angiotensin II-induced AAAs than males.

143 a multifaceted therapeutic effect to prevent angiotensin II-induced cardiac dysfunction by improving

144 BMMO-derived HuR-deficient exosomes inhibits angiotensin II-induced cardiac fibrosis response and pre

145 eration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.

146 Angiotensin II-induced hypertension was associated with

147 The angiotensin II-induced hypertension was attenuated by co

148 Although Angiotensin II-induced hypertension was blunted in PAI-1

149 The effect of the alphaAnalogue on angiotensin II-induced hypertension was investigated ove

150 In animal models of nitrate tolerance and angiotensin II-induced hypertension, decreased vasodilat

151 loid-specific Nox2 deletion had no effect on angiotensin II-induced hypertension, which, however, was

152 al cells, and contributes to protection from angiotensin II-induced hypertension.

153 ox2, whereas endothelial cell Nox2 regulates angiotensin II-induced hypertension.

154 the hypoxia-inducible factor complex, during angiotensin II-induced hypertensive nephropathy provided

155 NRP1 contributes to protection from low-dose angiotensin II-induced increases in blood pressure.

156 ealed that VEGFCc156s specifically modulated angiotensin II-induced inflammatory responses in cardiac

157 Mechanistically, angiotensin II-induced podocyte cytoskeleton reorganizat

158 or signaling, in cultured fibroblasts and in angiotensin II-induced skin and heart fibrosis.

159 Oxidized LDL (a LOX-1 ligand) increased angiotensin II-induced vasoconstriction in STBEV-incubat

160 Angiotensin II-infused apoE(-/-) (n = 16) mice were used

161 Systemic delivery of anti-miR-181b in angiotensin II-infused Apoe(-/-) and Ldlr(-/-) mice atte

162 were abrogated in regulatory T cell-depleted angiotensin II-infused mice, suggesting the effect is re

163 prevented increased cardiac MC maturation in angiotensin II-infused mice.

164 significantly reduced in propionate-treated angiotensin II-infused wild-type NMRI mice.

165 on coculture with dendritic cells from Ang (angiotensin) II-infused mice, were reduced in denervated

166 Angiotensin II infusion in apoE(-/-) mice for 4 wk resul

167 Following angiotensin II infusion in mice, we found that an affini

168 Here, we demonstrate that angiotensin II infusion induced cardiac inflammation and

169 Moreover, angiotensin II infusion instigated interferon-gamma, whi

170 n spontaneously hypertensive rat and chronic angiotensin II infusion rat models.

171 sporadic AAD induced by a high-fat diet and angiotensin II infusion, ADAMTS-4 deficiency (Adamts-4-/

172 , transverse aortic constriction banding and angiotensin II infusion, and a genetic model of Etv1 car

173 Muscle regeneration was delayed by angiotensin II infusion, mimicking aging and CHF as repo

174 level, they were more sensitive to low-dose angiotensin II infusion-induced increases in blood press

175 ion or chronic neurohormonal stimulation via Angiotensin II infusion.

176 Angiotensin-II infusion also caused RhoBTB1-deficiency a

177 e subjected to pressure overload by means of angiotensin-II infusion or transversal aortic constricti

178 r increases in aldosterone in response to an angiotensin-II infusion than did men.

179 testosterone as neonates or as adults before angiotensin II infusions.

180 asma renin activity drawn immediately before angiotensin II initiation was 40 ng/mL/hr (normal, 0.6-3

181 to 22 and 12 ng/mL/hr at 2 and 6 hours after angiotensin II initiation, respectively.

182 dentified ACE2 as the main enzyme converting angiotensin II into angiotensin-(1-7) in human cerebrosp

183 We infused angiotensin II into endothelial-selective Epas1 knockout

184 e A inhibitor preventing conversion of brain angiotensin-II into angiotensin-III, in BP lowering in a

185 Angiotensin II is an endogenous hormone with vasopressor

186 Moreover, although angiotensin II is the classic effector molecule of the R

187 Infusion of angiotensin II led to aortic medial hemorrhage and disse

188 ion and in association with elevated Ang II (angiotensin II) levels.

189 The acute infusion of angiotensin II markedly increased the incidence of AAA i

190 perivascular tissues in response to Ang II (angiotensin II)-mediated hypertension, miR-214 showed th

191 blood pressure independent of alterations in angiotensin II-mediated aortic stiffness.

192 endogenous and synthetic agonists inhibited angiotensin II-mediated G-protein-associated second mess

193 unappreciated roles for Micu2 in regulating angiotensin II-mediated hypertensive responses that are

194 itro findings were confirmed in vivo with an angiotensin II-mediated murine model of cardiac fibrosis

195 protein-coupled receptor agonists, including angiotensin II or bombesin, induced rapid and persistent

196 ations before the start of administration of angiotensin II or placebo and after 3 hours.Measurements

197 In mice challenged with angiotensin II, PDGF receptor alpha-positive cells were

198 myocyte pathological hypertrophy induced by Angiotensin II, phenylephrine, and isoproterenol, but di

199 Finally, we show that the enhanced angiotensin II plays an important role in the intracellu

200 Here, we find that the local angiotensin II predominantly exists in the hypoxic regio

201 angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT(2)R), the proto-oncogene Mas

202 Activation of the type 1 angiotensin II receptor (AT1) triggers proinflammatory s

203 Losartan, a type I angiotensin II receptor (AT1R) antagonist, has been prev

204 a key intermediate for accessing a class of angiotensin II receptor 1 antagonists.

205 damage, and suppression of cardio-reparative Angiotensin II receptor 2 (Agtr2).

206 Angiotensin II receptor activation may result in angioge

207 GPCRs, such as beta-adrenergic receptor and angiotensin II receptor antagonists.

208 giotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin recep

209 laboratory monitoring after ACE inhibitor or angiotensin II receptor blocker initiation was not assoc

210 ut more expensive, heart failure medication (angiotensin II receptor blocker neprilysin inhibitor).

211 f angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy and glucose-lowe

212 51 matched pairs initiating ACE inhibitor or angiotensin II receptor blocker therapy between January

213 the 30 days after starting ACE inhibitor or angiotensin II receptor blocker therapy were matched 1:1

214 (angiotensin-converting enzyme) inhibitor or angiotensin II receptor blocker therapy.

215 o angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentia

216 [angiotensin-converting enzyme] inhibitor or angiotensin II receptor blocker) and a newer, but more e

217 otensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker), be switched to sacubit

218 the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

219 ensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitaliz

220 giotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers an

221 ensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) does not increas

222 ensin-converting enzyme (ACEs) inhibitors or angiotensin II receptor blockers (ARBs) in CKD is lackin

223 oV-2 positive test result compared to use of angiotensin II receptor blockers (OR = 0.70, 95% CI 0.54

224 Angiotensin II receptor blockers are beneficial in patie

225 We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on ad

226 sed case-control study indicates that use of angiotensin II receptor blockers might be associated wit

227 The effect of angiotensin II receptor blockers on right ventricular (R

228 reatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decre

229 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potentia

230 Because angiotensin II receptor blockers, ACE inhibitors, and mi

231 titis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-use

232 angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, beta-blockers, thiazid

233 e collected from patients, with attention to angiotensin II receptor blockers, such as olmesartan, al

234 cal research suggests a protective effect of angiotensin II receptor blockers.

235 induced ER stress and inflammation, whereas angiotensin II receptor inhibitor, telmisartan reduced R

236 d type, P = 7.8 x 10(-40)), which suppresses angiotensin II receptor signaling via allosteric transin

237 data analysis identified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-I

238 -2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated

239 Substantial evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mec

240 n, and LOX-1 has been shown to interact with angiotensin II receptor type 1 (AT1).

241 ay, we characterize a GPCR-TRP channel pair, angiotensin II receptor type 1 (AT1R), and transient rec

242 027, a beta-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute

243 it intracellular calcium release mediated by angiotensin II receptor type 1 (AT1R).

244 induced sympathoexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glu

245 cation of Telmisartan (an antagonist for the angiotensin II receptor) through copper-mediated C-H ami

246 0067, a beta-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II

247 nregulated collectrin expression in a type 1 angiotensin II receptor-dependent manner.

248 ngiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers may be less effe

249 ngiotensin-I converting enzyme inhibitors or angiotensin-II receptor type 1 blockers.

250 The angiotensin II receptors AT1R and AT2R serve as key comp

251 Exogenous angiotensin II reduced catecholamine vasopressor doses a

252 Thus, STBEVs reduced angiotensin II responsiveness in normal pregnancy, but n

253 STBEV-incubation decreased angiotensin II responsiveness only in wildtype mice, whi

254 Activation of either AT1 Ra or AT1 Rb with angiotensin II stimulates TRPM4 currents in cerebral art

255 n of endothelium-dependent relaxation during angiotensin II stimulation.

256 ween endogenous renin activity and exogenous angiotensin II supplementation.

257 e ACE2, leading to toxic overaccumulation of angiotensin II that induces acute respiratory distress s

258 Compared to angiotensin II, the endogenous agonist, agonists with en

259 At 3 hours after initiation of angiotensin II therapy, there was a 54.3% reduction (IQR

260 nsors by allowing the short cationic peptide angiotensin II to be electrophoretically driven through

261 2 cleaves many biological substrates besides angiotensin II to control vasodilatation and vascular pe

262 treatment in hypertrophy samples, including angiotensin II-treated adult cardiac fibroblasts and ren

263 tration of small-molecule Plk1 inhibitors to angiotensin II-treated mice led to reduced arterial fitn

264 sets from transverse aortic constriction and angiotensin II-treated mice showed a high Pearson correl

265 eatment model of AAA in C57BL6 (WT) mice and Angiotensin II treatment model in ApoE(-/-) mice were us

266 s and shifts in cellular communication after angiotensin II treatment that promote the development of

267 After angiotensin II treatment, Fibroblast-Cilp develops as th

268 enzyme with an ACE inhibitor but not with an angiotensin II type 1 (AT1) receptor antagonist.

269 (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AGTR1), and aldosterone

270 hese mice had increased renal expressions of angiotensin II type 1 receptor (AT(1) R), NADPH oxidase

271 this work, we present crystal structures of angiotensin II type 1 receptor (AT1R) (2.7 to 2.9 angstr

272 Angiotensin II type 1 receptor (AT1R) blockers (ARBs) ar

273 The angiotensin II type 1 receptor (AT1R) is notable as it h

274 We recently reported that angiotensin II type 1 receptor (AT1R)-associated protein

275 le nanobodies that act as antagonists of the angiotensin II type 1 receptor (AT1R).

276 track activation and internalization of the angiotensin II type 1 receptor and the beta2 adrenocepto

277 aintained despite RVLM pretreatment with the angiotensin II type 1 receptor antagonist losartan, the

278 tics of graft injury in the presence of anti-angiotensin II type 1 receptor antibody (AT1R-Ab) and an

279 Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs)

280 VLM of normotensive rats is not mediated via angiotensin II type 1 receptor, oxytocin, ionotropic glu

281 rrestin bias and G protein bias arise at the angiotensin II type 1 receptor.

282 occurs selectively on neurons, and neuronal angiotensin II type 1 receptors are indispensable to thi

283 Our data demonstrate that angiotensin II type 1 receptors promote ADAM17-mediated

284 system and ADAM17, we generated mice lacking angiotensin II type 1 receptors specifically on neurons.

285 th muscle cells (SMCs): thromboxane A(2) and angiotensin II type 1.

286 havioral approaches, we examined the role of angiotensin II type 2 receptor (AT(2)R) in fear-related

287 ce in the conformational distribution of the angiotensin II type I receptor.

288 Angiotensin II type-1 receptor (AT1R) antibodies have be

289 Isolated de novo anti-angiotensin II type-1 receptor and anti-endothelin-1 typ

290 0 to 4 of 2009 with known HLA DSA status for angiotensin II type-1 receptor and endothelin-1 type A r

291 HLA antibodies, including antibodies against angiotensin-II type 1 receptor, did not contribute to ri

292 ], Rho guanine nucleotide exchange factor 6, angiotensin-II type 1 receptor, endothelin type A recept

293 were made hypertensive by administration of angiotensin II via osmotic mini-pumps and blood pressure

294 Ang II (angiotensin II) was infused subcutaneously using osmotic

295 Adverse events associated with angiotensin II were infrequent; however, exacerbation of

296 other serious adverse events attributable to angiotensin II were reported.

297 Studies in which human subjects received IV angiotensin II were selected whether or not safety was d

298 ation events by altering the balance between angiotensin II, which activates angiotensin receptor typ

299 ngiotensin I into the potent vasoconstrictor angiotensin II, which regulates blood pressure.

300 angiotensin I to the potent vasoconstrictor angiotensin II while simultaneously halting the NEP-depe

301 wall shear stress, and exogenous sources of angiotensin II, with particular interest in mouse models